Read by QxMD icon Read


Paaladinesh Thavendiranathan
No abstract text is available yet for this article.
March 9, 2018: JACC. Cardiovascular Imaging
Jessica M Scott, Tormod S Nilsen, Dipti Gupta, Lee W Jones
Cardio-oncology is an emerging discipline focused predominantly on the detection and management of cancer treatment-induced cardiac dysfunction (cardiotoxicity), which predisposes to development of overt heart failure or coronary artery disease. The direct adverse consequences, as well as those secondary to anticancer therapeutics, extend beyond the heart, however, to affect the entire cardiovascular-skeletal muscle axis (ie, whole-organism cardiovascular toxicity). The global nature of impairment creates a strong rationale for treatment strategies that augment or preserve global cardiovascular reserve capacity...
March 13, 2018: Circulation
Maria Laura Canale, Chiara Lestuzzi, Irma Bisceglia, Paola Vallerio, Iris Parrini
AIMS: Cardio-oncology is imposing as the specialty deputed to the management of a large and rapidly increasing population of cancer patients receiving anticancer treatments with cardiovascular side effects or presenting with cardiac and oncological comorbidities. Organization patterns dramatically vary across Italy. METHODS: On the behalf of ANMCO, we have analyzed the characteristics of cardio-oncology services across different hospital types in Italy. A questionnaire was sent out to all ANMCO divisions inquiring about inner organization, workload, multidisciplinary team and inter-hospital connections...
March 9, 2018: Journal of Cardiovascular Medicine
Suparna C Clasen, Joyce W Wald
PURPOSE OF REVIEW: We aim to summarize the effect of cancer therapy-related cardiotoxicity on the development of left ventricular (LV) dysfunction. RECENT FINDINGS: We discuss commonly used cancer therapeutics that have the potential for both acute and delayed cardiotoxicity. LV dysfunction from cancer therapies may be found by routine cardiac imaging prior to clinical manifestations of heart failure (HF) and we discuss the current multi-modality approaches for early detection of toxicity with the use of advanced echocardiographic parameters including strain techniques...
March 8, 2018: Current Cardiology Reports
Nathalie Donis, Cécile Oury, Marie Moonen, Patrizio Lancellotti
Available data indicate that survivors of breast cancer and Hodgkin lymphoma who received mediastinal radiotherapy are at increased risk of developing radiation-induced cardiovascular diseases (RICVD) one or two decades after treatment. Although the risk with modern radiation treatment is likely to be lower in these patient groups, cardiotoxicity is still observed in a subset of patients. In addition, radiation-associated cardiovascular complications can, in the future, extend to other groups of cancer patients who are treated for tumors that are localized near the heart...
March 1, 2018: Expert Opinion on Pharmacotherapy
Valentin Fuster
Each week, I record audio summaries for every article in JACC, as well as an issue summary. While this process has been time-consuming, I have become quite familiar with every paper that we publish. Thus, I personally select papers (both original investigations and review articles) from 15 distinct specialties each year for your review. In addition to my personal choices, I have included manuscripts that have been the most accessed or downloaded on our websites, as well as those selected by the JACC Editorial Board members...
February 27, 2018: Journal of the American College of Cardiology
Pietro Ameri, Marco Canepa, Markus S Anker, Yury Belenkov, Jutta Bergler-Klein, Alain Cohen-Solal, Dimitrios Farmakis, Teresa López-Fernández, Mitja Lainscak, Radek Pudil, Frank Ruschitska, Petar Seferovic, Gerasimos Filippatos, Andrew Coats, Thomas Suter, Stephan Von Haehling, Fortunato Ciardiello, Rudolf A de Boer, Alexander R Lyon, Carlo G Tocchetti
Cancer and heart failure (HF) are common medical conditions with a steadily rising prevalence in industrialized countries, particularly in the elderly, and they both potentially carry a poor prognosis. A new diagnosis of malignancy in subjects with pre-existing HF is not infrequent, and challenges HF specialists as well as oncologists with complex questions relating to both HF and cancer management. An increased incidence of cancer in patients with established HF has also been suggested. This review paper summarizes the epidemiology and the prognostic implications of cancer occurrence in HF, the impact of pre-existing HF on cancer treatment decisions and the impact of cancer on HF therapeutic options, while providing some practical suggestions regarding patient care and highlighting gaps in knowledge...
February 21, 2018: European Journal of Heart Failure
Lucia Venneri, Giacomo Zoppellaro, Rajdeep S Khattar
Cardio-oncology is a rapidly growing field aimed at improving the quality of care of cancer patients by preventing and monitoring cardiovascular complications resulting from cancer treatment. Cardiac imaging, and in particular, transthoracic echocardiography, plays an essential
role in the baseline assessment and serial follow-up of cardio-oncology patients. Areas covered: This review article discusses the role of cardiac imaging with a focus on advanced echocardiography for the detection and management of cancer therapy related cardiovascular complications, in particular, left ventricular dysfunction and heart failure...
February 22, 2018: Expert Review of Cardiovascular Therapy
Lisa M Tilemann, Markus B Heckmann, Hugo A Katus, Lorenz H Lehmann, Oliver J Müller
BACKGROUND: This article about the emerging field of cardio-oncology highlights typical side effects of oncological therapies in the cardiovascular system, cardiovascular complications of malignancies itself, and potential preventive or therapeutic modalities. METHODS: We performed a selective literature search in PubMed until September 2016. RESULTS: Cardiovascular events in cancer patients can be frequently attributed to oncological therapies or to the underlying malignancy itself...
February 16, 2018: Clinical Research in Cardiology: Official Journal of the German Cardiac Society
Vito Calabrese, Pierantonio Menna, Ombretta Annibali, Grazia Armento, Armando Carpino, Elisabetta Cerchiara, Carlo Greco, Francesco Marchesi, Paolo Spallarossa, Giuseppe Toglia, Giorgio Reggiardo, Giorgio Minotti
Asymptomatic diastolic dysfunction (DD) with preserved left ventricular ejection fraction (LVEF) is suspected to precede late cardiac events in cancer survivors treated by chemotherapy. We conducted the first multicenter study of early DD induced by chemotherapy. Patients who were candidates for standard dose chemotherapy were screened for the absence of cardiovascular risk factors, LVEF ≥50%, normal-for-age diastolic function at echocardiography (E/A ratio, E wave deceleration time; DT), normal levels of potential DD biomarkers like Nt-proBNP (≤125 pg/mL), and cardiac troponin I (cTnI, ≤0...
February 9, 2018: Chemotherapy
Stephen A Geraci
No abstract text is available yet for this article.
February 6, 2018: American Journal of Medicine
Timothy M Markman, Maurie Markman
The therapeutic options available to treat a wide range of malignancies are rapidly increasing. At the same time, the population being treated is aging with more cardiovascular risk factors, comorbid conditions, and associated poor cardiac reserve. Both traditional chemotherapeutic agents (for example, anthracyclines) and newer therapies (for example, targeted tyrosine kinase inhibitors and immune checkpoint inhibitors) have demonstrated profound cardiovascular toxicities. It is important to understand the mechanisms of these toxicities to establish strategies for the prevention and management of complications-arrhythmias, heart failure, and even death...
2018: F1000Research
Michel G Khouri, Bonnie Ky, Gary Dunn, Ted Plappert, Virginia Englefield, Dawn Rabineau, Eric Yow, Huiman X Barnhart, Martin St John Sutton, Pamela S Douglas
BACKGROUND: As the potential for cancer therapy-related cardiac dysfunction is increasingly recognized, there is a need for the standardization of echocardiographic measurements and cut points to guide treatment. The aim of this study was to determine the reproducibility of cardiac safety assessments across two academic echocardiography core laboratories (ECLs) at the University of Pennsylvania and the Duke Clinical Research Institute. METHODS: To harmonize the application of guideline-recommended measurement conventions, the ECLs conducted multiple training sessions to align measurement practices for traditional and emerging assessments of left ventricular (LV) function...
March 2018: Journal of the American Society of Echocardiography
Radek Pudil
Cardiovascular (CV) disease and cancer remain the two most common causes of mortality in developed countries; however, progress in the treatment of malignant diseases significantly improved survival of oncological patients. Similarly, there is an increased number of the patients with malignancy who have a history of CV disease or an increased CV risk. Rates of CV problems from cancer-related therapeutics are high, and cardiotoxicity is the second most common cause of morbidity and mortality in cancer survivors...
November 2017: Cardiac Failure Review
Chikashi Ishioka
Cancer and cardiovascular disease are 2 major disease of the Japanese cause of death. Both patients with cancer complicated with cardiovascular disease and patients with cancer developing cardiovascular disorder during cancer therapyare increasing recently. Because aging is the onset risk factor, as for these, it is predicted that the patients with both cancer and cardiovascular disease increase more and more by the arrival of the aging society. Recently, the new research field called cardiooncology( or onco-cardiology)has been established, and the cooperation of medical oncologist and cardiologist becomes indispensable...
December 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
Carol Chen-Scarabelli, William G Hundley, Tiziano M Scarabelli
No abstract text is available yet for this article.
January 22, 2018: Future Cardiology
James Marangou, Andrew Redfern, Tony Haddad, James M Rankin, Girish Dwivedi
PURPOSE OF REVIEW: The aim of this review is to give the reader an up-to-date overview of the progress made in the burgeoning field of cardio-oncology, encompassing oncological treatments conferring risk, prediction strategies to identify patients at risk, imaging and biomarker monitoring for emergent or subclinical toxicity and prevention in primary and secondary settings with a focus on heart failure. RECENT FINDINGS: The rapid recent advances in cancer management, particularly with the expansion of targeted and immunotherapies, have led to substantial improvements in outcome, but have also added to the potential causes of cardiac toxicity, which can lead to heart failure...
March 2018: Current Opinion in Cardiology
Andreu Porta-Sánchez, Cameron Gilbert, Danna Spears, Eitan Amir, Joyce Chan, Kumaraswamy Nanthakumar, Paaladinesh Thavendiranathan
BACKGROUND: The cardiovascular complications of cancer therapeutics are the focus of the burgeoning field of cardio-oncology. A common challenge in this field is the impact of cancer drugs on cardiac repolarization (ie, QT prolongation) and the potential risk for the life-threatening arrhythmia torsades de pointes. Although QT prolongation is not a perfect marker of arrhythmia risk, this has become a primary safety metric among oncologists. Cardiologists caring for patients receiving cancer treatment should become familiar with the drugs associated with QT prolongation, its incidence, and appropriate management strategies to provide meaningful consultation in this complex clinical scenario...
December 7, 2017: Journal of the American Heart Association
Noriaki Tabata, Daisuke Sueta, Eiichiro Yamamoto, Seiji Takashio, Yuichiro Arima, Satoshi Araki, Kenshi Yamanaga, Masanobu Ishii, Kenji Sakamoto, Hisanori Kanazawa, Koichiro Fujisue, Shinsuke Hanatani, Hirofumi Soejima, Seiji Hokimoto, Yasuhiro Izumiya, Sunao Kojima, Hiroshige Yamabe, Koichi Kaikita, Kenichi Tsujita
Background: As progress is made in successfully treating cancer, there is increasing need to focus on the risk and complexity of treating cardiovascular events in cancer survivors - thus, the field of onco-cardiology/cardio-oncology has emerged. We examined the differential incidence of cardiovascular events after percutaneous coronary intervention (PCI) in patients with or without cancer. Methods and Results: Participants were divided into a non-cancer group and a cancer group, which consisted of patients who were receiving or had ever received cancer treatment...
December 1, 2017: European Heart Journal. Quality of Care & Clinical Outcomes
Teresa López-Fernández, Ana Martin-García, Sonia Velasco Del Castillo, Cristina Mitroi
No abstract text is available yet for this article.
January 2018: Revista Española de Cardiología
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"